Don’t know about that BipolarCat1 last raise was dropped a week...

Don’t know about that BipolarCat1 last raise was dropped a week after an announcement to market the company was being pursued for IP infringements in the Federal court…not exactly an ideal piece of news or position of strength to try raise off retail investors. Still managed just shy of $5M even with a very dark cloud over their heads.

They also had plans for a pilot plant, but nothing built.
Plant is now built undergoing commissioning, court matters are resolved and the company retained all the rights to its own exceptional IP. (IP worth a multinational trying to go after it in the federal courts)

Whilst further cap raises are obviously much less preferable to a grant or an equity stake, or an ongoing supply contract from either division that will cover expenses. I don’t think they would have too much trouble raising, the sun is shining through the clouds again now they have legal issue in the rear view and pilot plant commissioning underway. When they can produce AnteoX at scale that will be the final TRL hurdle ticked off the list…wonder what happens then…bring it on.

There is also still a dedicated life science team in the building toiling away on something…I look forward to seeing your sentiment change back to buy again soon.

GLTA